High-Risk Localized and Locally Advanced Prostate Cancer

<p>Around 20%-30% of nonmetastatic prostate cancer patients have high-risk localized disease. The best treatment for high-risk localized disease is still unclear and the reliability of the definition of high-risk may need to be validated first. Although recent advances in radiotherapy for prostate cancer have yielded excellent long-term results even in high-risk localized disease there are no studies directly comparing it with local treatment options such as prostatectomy. To address current challenges in high-risk localized and locally advanced prostate cancer 12 original and 3 review articles covering aspects from basic research to clinical trials are published in this Special Issue.</p>